{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:33:09Z","timestamp":1793871189712,"version":"4.6.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["5R35GM140862"],"award-info":[{"award-number":["5R35GM140862"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omtn.2026.103052","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:23:09Z","timestamp":1785885789000},"page":"103052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["ESCRT-I complex enhances therapeutic efficacy of ASO drugs by regulating endosomal escape and glucose homeostasis"],"prefix":"10.1016","volume":"37","author":[{"given":"Le Tra Giang","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8340-0531","authenticated-orcid":false,"given":"Sherouk M.","family":"Tawfik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2511-5648","authenticated-orcid":false,"given":"Andrea","family":"Durwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beshoy","family":"Armanios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6537-5415","authenticated-orcid":false,"given":"Xiao-bo","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.103052_bib1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.omtn.2026.103052_bib2","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: An emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.omtn.2026.103052_bib3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s40259-024-00665-2","article-title":"Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs","volume":"38","author":"Sang","year":"2024","journal-title":"BioDrugs."},{"key":"10.1016\/j.omtn.2026.103052_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pharmrev.123.000815","article-title":"Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin","volume":"76","author":"Gogate","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.omtn.2026.103052_bib5","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.molcel.2019.12.011","article-title":"Antisense-Mediated Transcript Knockdown Triggers Premature Transcription Termination","volume":"77","author":"Lee","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omtn.2026.103052_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10974-024-09688-2","article-title":"Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy","volume":"46","author":"Chwalenia","year":"2025","journal-title":"J. Muscle Res. Cell Motil."},{"key":"10.1016\/j.omtn.2026.103052_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100938","article-title":"Antisense and gene therapy trials in Duchenne muscular dystrophy","volume":"6","author":"Scoto","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.omtn.2026.103052_bib8","doi-asserted-by":"crossref","first-page":"R163","DOI":"10.1093\/hmg\/ddy171","article-title":"Exon-skipping advances for Duchenne muscular dystrophy","volume":"27","author":"Echevarr\u00eda","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2026.103052_bib9","doi-asserted-by":"crossref","DOI":"10.52965\/001c.24934","article-title":"The antisense oligonucleotide nusinersen for treatment of spinal muscular atrophy","volume":"13","author":"Edinoff","year":"2021","journal-title":"Orthop. Rev."},{"key":"10.1016\/j.omtn.2026.103052_bib10","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.tips.2023.08.008","article-title":"ASO drug Qalsody (tofersen) targets amyotrophic lateral sclerosis","volume":"44","author":"Jin","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.omtn.2026.103052_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.75.1.285","article-title":"Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide","volume":"75","author":"Stephenson","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103052_bib12","doi-asserted-by":"crossref","first-page":"7779","DOI":"10.1073\/pnas.1505629112","article-title":"Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment","volume":"112","author":"Zhu","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103052_bib13","doi-asserted-by":"crossref","DOI":"10.1021\/nn3049494","article-title":"Mechanism of polyplex- and lipoplex-mediated delivery of nucleic acids: Real-time visualization of transient membrane destabilization without endosomal lysis","volume":"7","author":"Rehman","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.omtn.2026.103052_bib14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.omtn.2016.12.003","article-title":"Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics","volume":"6","author":"Huang","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103052_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/VHRM.S191965","article-title":"Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes","volume":"18","author":"Chambergo-Michilot","year":"2022","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.omtn.2026.103052_bib16","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/dmd.121.000418","article-title":"Adverse Drug Reactions and Toxicity of the Food and Drug Administration\u2013Approved Antisense Oligonucleotide Drugs","volume":"50","author":"Alhamadani","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.omtn.2026.103052_bib17","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/17425255.2021.1992382","article-title":"Antisense oligonucleotides: absorption, distribution, metabolism, and excretion","volume":"17","author":"Shadid","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.omtn.2026.103052_bib18","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1124\/dmd.121.000417","article-title":"Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration\u2013Approved Antisense Oligonucleotide Drugs","volume":"50","author":"Migliorati","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.omtn.2026.103052_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/nat.2022.0054","article-title":"Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs","volume":"33","author":"Takakusa","year":"2023","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2026.103052_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.addr.2015.12.004","article-title":"Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines","volume":"104","author":"Park","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2026.103052_bib21","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1089\/nat.2018.0727","article-title":"Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don\u2019t","volume":"28","author":"Juliano","year":"2018","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2026.103052_bib22","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1261\/rna.079507.122","article-title":"Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?","volume":"29","author":"Dowdy","year":"2023","journal-title":"RNA"},{"key":"10.1016\/j.omtn.2026.103052_bib23","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1093\/nar\/gkv143","article-title":"Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages","volume":"43","author":"Liang","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103052_bib24","first-page":"7314","article-title":"Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides","volume":"44","author":"Wang","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103052_bib25","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/nar\/gkac774","article-title":"Structures of annexin A2-PS DNA complexes show dominance of hydrophobic interactions in phosphorothioate binding","volume":"51","author":"Hyjek-Sk\u0142adanowska","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103052_bib26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.omtn.2023.03.017","article-title":"GOLGA8 increases bulk antisense oligonucleotide uptake and activity in mammalian cells","volume":"32","author":"McMahon","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103052_bib27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nrm2162","article-title":"The emerging shape of the ESCRT machinery","volume":"8","author":"Williams","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2026.103052_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.devcel.2011.05.015","article-title":"The ESCRT Pathway","volume":"21","author":"Henne","year":"2011","journal-title":"Dev. Cell"},{"key":"10.1016\/j.omtn.2026.103052_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0092-8674(01)00434-2","article-title":"Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I","volume":"106","author":"Katzmann","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103052_bib30","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/nar\/gku1367","article-title":"Identification of the endosomal sorting complex required for transport-I (ESCRT-I) as an important modulator of anti-miR uptake by cancer cells","volume":"43","author":"Wagenaar","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103052_bib31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-014-3451-1","article-title":"GLUT2, glucose sensing and glucose homeostasis","volume":"58","author":"Thorens","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.omtn.2026.103052_bib32","doi-asserted-by":"crossref","first-page":"E985","DOI":"10.1152\/ajpendo.00004.2009","article-title":"GLUT2 mutations, translocation, and receptor function in diet sugar managing","volume":"296","author":"Leturque","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.omtn.2026.103052_bib33","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3390\/cells9091936","article-title":"Tsg101 is involved in the sorting and re-distribution of glucose transporter-4 to the sarcolemma membrane of cardiac myocytes","volume":"9","author":"Essandoh","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2026.103052_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102487","article-title":"Impact on efficacy of target reduction of two FDA-approved ASO drugs by intracellular glucose levels in in vitro cell models","volume":"36","author":"Nguyen","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103052_bib35","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103052_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1083\/jcb.200811130","article-title":"ESCRT ubiquitin-binding domains function cooperatively during MVB cargo sorting","volume":"185","author":"Shields","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.omtn.2026.103052_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cell.2006.01.049","article-title":"Structural and Functional Organization of the ESCRT-I Trafficking Complex","volume":"125","author":"Kostelansky","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103052_bib38","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1091\/mbc.e06-07-0588","article-title":"Efficient cargo sorting by ESCRT-I and the subsequent release of ESCRT-I from multivesicular bodies requires the subunit Mvb12","volume":"18","author":"Curtiss","year":"2007","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.omtn.2026.103052_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2026.102832","article-title":"Identification and functional validation of intracellular protein partners of phosphorothioate splice-switching oligonucleotides using AP-MS","volume":"37","author":"Gaci","year":"2026","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103052_bib40","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41589-023-01530-z","article-title":"Profiling the interactome of oligonucleotide drugs by proximity biotinylation","volume":"20","author":"Hanswillemenke","year":"2024","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.omtn.2026.103052_bib41","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/cells5030034","article-title":"Multiple roles of the small GTPase Rab7","volume":"5","author":"Guerra","year":"2016","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2026.103052_bib42","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/BSR20090032","article-title":"Rab7: Roles in membrane trafficking and disease","volume":"29","author":"Zhang","year":"2009","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.omtn.2026.103052_bib43","article-title":"Depletion of TSG101 forms a mammalian \u2018class E\u2019 compartment: A multicisternal early endosome with multiple sorting defects","volume":"118","author":"Doyette","year":"2005","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.omtn.2026.103052_bib44","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.omtn.2026.103052_bib45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.omtn.2026.103052_bib46","first-page":"119","article-title":"Mipomersen (Kynamro): A novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia","volume":"39","author":"Wong","year":"2014","journal-title":"Pharmacy Therapeutics"},{"key":"10.1016\/j.omtn.2026.103052_bib47","series-title":"Protocols in in Vitro Hepatocyte Research","article-title":"Culture and functional characterization of human hepatoma HepG2 cells","author":"Donato","year":"2015"},{"key":"10.1016\/j.omtn.2026.103052_bib48","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1124\/dmd.109.031831","article-title":"A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues","volume":"38","author":"Hart","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.omtn.2026.103052_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174227","article-title":"Critical Investigation of the Usability of Hepatoma Cell Lines HepG2 and Huh7 as Models for the Metabolic Representation of Resectable Hepatocellular Carcinoma","volume":"14","author":"Schicht","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:08:38Z","timestamp":1788880118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126002234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2162253126002234"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103052","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESCRT-I complex enhances therapeutic efficacy of ASO drugs by regulating endosomal escape and glucose homeostasis","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"103052"}}